Caris Life Sciences, a cancer diagnostics and treatment biotech, is targeting a nearly $5.35 billion valuation in an IPO — 30% less than it was worth in 2021.
Why it matters: The public markets may be reopening to biotech, a sector that's been struggling amid a set of macro challenges.
